Enhancement of effects of WT1 peptide-based immunotherapy for malignant glioma.

• Project/Area Number: 26462179
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Neurosurgery
• Research Institution: Osaka University
• Principal Investigator: Tsuboi Akihiro 大阪大学, 医学系研究科, 寄附講座教授 (10372608)
• Co-Investigator(Kenkyū-buntansha): 橋本 直哉 京都府立医科大学, 医学(系)研究科(研究院), 教授 (90315945)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Project Status: Completed (Fiscal Year 2016)
• Budget Amount: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000); Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
• Keywords: ペプチドワクチン / 臨床試験 / ＷＴ１ / ヘルパーペプチド / 悪性神経膠腫 / 膠芽腫 / テモゾロミド / 腫瘍免疫 / 脳腫瘍

Outline of Final Research Achievements

We have investigated peptide based immunotherapy for malignant tumors targeting Wilms tumor 1 (WT1) that is expressed in almost malignancies including malignant glioma and has high immunogenicity. In this study, we have used not only HLA class I restricted two WT1 peptides but also HLA class II-restricted WT1 peptide (WT1 Trio Peptide) to enhance WT1 specific immune responses and performed two kinds of clinical study using the WT1 Trio Peptide for malignant glioma. One trial is WT1 Trio Peptide-vaccine for Rare Cancers. Patients with recurrent malignant glioma are enrolled in this study. The other one is Phase II clinical trial of WT1 peptide-based vaccine combined with Temozolomide for patients with newly diagnosed glioblastoma. Both studies are recruiting.